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Purpose. To assess the incidence of central serous chorioretinopathy (CSCR) following laser in situ keratomileusis (LASIK) and
photorefractive keratectomy (PRK). Methods. A chart review was performed to identify all patients with CSCR and a previous
history of LASIK or PRK. Results. Over the 6-year study period, 1 of 4,876 eyes which had LASIK or PRK at the Moran Eye Center
was diagnosed with CSCR. One other patient was referred from an outside center, developed CSCR symptoms one month after
PRK. Both patients were managed conservatively with a ﬁnal visual acuity of 20/20 or better. All other patients presented 4 or
more years after refractive surgery. Conclusions. We report the ﬁrst 2 CSCR cases developing within one month after PRK. The low
incidence argues against a causal association. Topical corticosteroids or anxiety may elevate cortisol levels presenting therapeutic
challenges for the management of CSCR after PRK or LASIK.
1.Introduction
Vitreoretinal pathology has rarely been observed after laser-
assisted in situ keratomileusis (LASIK) or photorefractive
keratectomy (PRK) [1]. Posterior segment complications are
more common in myopic eyes and no direct causal rela-
tionship with keratorefractive surgery has been established
[2]. Retinal breaks, rhegmatogenous detachments, posterior
vitreous detachments, choroidal neovascularization (CNV),
a n dv i t r e o u sh e m o r r h a g eh a v ea l lb e e nr e p o r t e d[ 1–3].
Central serous chorioretinopathy (CSCR) is generally a
self-limited disease with the majority of patients recovering
visual acuity to 20/30 or better within three months [4].
Approximately 4% of patients will present with binocular
involvement, while up to 40% may eventually have involve-
ment of the fellow eye [5]. Increased permeability of the
choroidal vessels and dysfunction of the retinal pigment epi-
thelium (RPE) have been observed with neurosensory retinal
detachment and pigment epithelial detachment. Chronic
cases of CSCR may develop RPE atrophy and rarely CNV
[6].Patientspresentwithcentralvisualaberrationsincluding
scotoma, metamorphopsia, dyschromatopsia, and microp-
sia [7]. Known risk factors for CSCR include “type A”
personality, pregnancy, and corticosteroid elevation either
endogenously or through exogenous corticosteroid use [8].
C S C Rh a sb e e nr e p o r t e di n4s e p a r a t ec a s er e p o r t sa f t e r
LASIK [9–12]. To date, there have not been any reports of
CSCR after PRK. The goal of this study was to report the
incidence of CSCR after both PRK and LASIK through a
retrospective chart review.
2. Methods andPatients
From January 2005 to December 2010, an ICD-9 code search
for CSCR (362.41) identiﬁed 250 CSCR patients seen at the
John A. Moran Eye Center. All patients had a comprehensive
evaluation by a retina specialist. A retrospective chart review
identiﬁed 7 patients with a prior history of refractive surgery.2 Journal of Ophthalmology
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Wang et
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al. [10] F; 20 LASIK −7.00 + 1.00 × 90 Saudi
Arabia 1 week OD PDT Unknown 20/200 Unknown 20/60
M: Male; F: Female; PRK: Photoreactive Keratectomy; LASIK: Laser-assisted in situ keratomileusis; PDT: Photodynamic Therapy; Laser: Focal
Photocoagulation; OD: Right Eye; OS: Left Eye; OU: Both Eyes; UDVA: Uncorrected distance visual acuity, BCVA: Best corrected visual acuity. Final UDVA
and BCVA were from the last recorded follow-up visit.
Patients’ age, sex, medication history, pre- and postrefractive
surgery exam ﬁndings, onset of CSCR symptoms, clinical
course, treatment, and visual outcomes were analyzed. The
University of Utah Hospital Institutional Review Board ap-
proved the research protocol in accordance with the tenets of
the Declaration of Helsinki.
Database billing records of the Moran Eye Center were
reviewed to determine the total number of LASIK and PRK
procedures performed during the 6-year study period. Prior
to 2008, a Hansatome microkeratome (Bausch & Lomb, Inc,
Rochester, NY) was used for ﬂap creation. Thereafter, the
IntraLase FS60 femtosecond laser (Abbott Medical Optics
(AMO), Santa Ana, CA) was utilized. Both PRK and LASIK
were performed with either the VISX Star S4 Custom-
Vue (AMO), LadarVision CustomCornea (Alcon Inc., Fort
Worth, TX), or the WaveLight Allegretto (Alcon, Inc.) exci-
mer laser platforms.
A l lM o r a nE y eC e n t e rr e f r a c t i v es u r g e ryp a t i e n t sa r er o u -
tinely followed at a minimum of 6 visits at 1 day, 1 week, 1,
3, 6, and 12 months after surgery. Any retinal complications
that are discovered during postoperative exams are routinely
referred to our institution’s retina service. Because of our
internal referral system, any CSCR complication after LASIK
or PRK would be identiﬁed in the review of retina record
visits.
A MEDLINE keyword search for CSCR and PRK or
LASIK identiﬁed all previously reported cases of CSCR after
LASIK or PRK in the literature.
3. Results
Of the 250 CSCR patients seen by the retina service, 7
patientswereidentiﬁedashavingaprevioushistoryofLASIK
or PRK at either the Moran Eye Center or an outside facility
(Table 1). All 7 patients were male with an average age of
37 years, and all presented with unilateral CSCR. All had
myopic keratorefractive treatment, and none had a previous
history of CSCR or documented oral, topical skin, or inhaled
corticosteroid use or other signiﬁcant medical history.
Only 2 patients (Patients 1 and 2) had onset of disease
within the immediate postoperative period of 1 month.
Details of their clinical courses are described below. The
remaining patients presented more than 4 years after refrac-
tive surgery and were not considered to have a potential
causal relationship. All 7 patients were followed at the Moran
Eye Center from the time of initial CSCR symptoms to
resolution or stabilization of disease. Two of the patients
received treatment with focal laser photocoagulation, while
5 resolved spontaneously without treatment. All 7 patients
improved to an uncorrected distance visual acuity (UDVA)
of 20/30 or better. Best corrected visual acuity (BCVA) was
not recorded in all patients.
From January 2005 to December 2010, there were 2,728
eyes which had LASIK, and 2,148 eyes that received PRK at
the Moran Eye Center. Only one of the combined 4,876 total
LASIK and PRK cases at our institution developed CSCR
within one month. The annual incidence of CSCR over the
6-year study period was calculated to be 3.4 per 100,000 eyes
for both PRK and LASIK cases, and 7.8 per 100,000 eyes of
only PRK cases.
A comprehensive literature search revealed 4 other re-
ports of CSCR after LASIK; however, long-term recovery was
not available in all cases (Table 1). Two patients presented
with bilateral CSCR [10, 11] and 1 patient developed a rapid
onset of CSCR with CNV one week following LASIK [12].
4. Patient 1
This is a 37-year-old male with an unknown employment
who underwent PRK in September 2010 with a preoperative
manifest refraction of −4.50 + 0.25 × 134 and −4.50
sphere, right and left eyes, respectively. Dilated fundus exam
noted nonspeciﬁc RPE clumping in the left macula. On
postoperative day 1, UDVA was 20/20 in both eyes. TheJournal of Ophthalmology 3
Figure 1: Fundus photograph and optical coherence tomography
of the left eye of Patient 1, 19 days after PRK, showing serous retinal
detachment consistent with CSCR.
patient was started on prednisolone acetate 1% (Allergan
Inc., Irvine, CA), 4 times a day for one month. Nineteen
daysafterPRK,thepatientreportedcentralmetamorphopsia
in his left eye. BCVA was 20/40 in the left eye with
manifest refraction of −0.50 sphere. Anterior segment exam
showed clear corneas without epithelial defects or stromal
haze.
Spectral domain optical coherence tomography (sd-
OCT, Heidelberg Engineering, Heidelberg, Germany) dem-
onstrated subretinal ﬂuid accumulation consistent with
CSCR (Figure 1) in the aﬀected eye. No abnormalities were
seen in the right eye. Consultation with a retina specialist
led to the decision to keep the patient on standard corti-
costeroids drops with close observation. After one month,
the patient was switched to ﬂuorometholone 0.1% (Allergan
Inc.) 4 times daily which was tapered over the next 6
weeks.Histotalpostoperativecorticosteroidexposurewas12
weeks.
UDVA improved to 20/20 bilaterally 1 month after initial
symptoms with complete resolution of metamorphopsia by
5 months after PRK. Eight months after PRK, UDVA was
20/20 in both eyes. The patient reported a mild recurrence
of central visual distortion in the left eye. Anterior and
posterior segment exam and sd-OCT ﬁndings were normal
and the patient was advised to monitor his symptoms
without further intervention.
5. Patient 2
This is a 28-year-old male lab technician who underwent
PRK at an outside facility in August 2009. His preoperative
manifest refraction was −4.50+1.00×90 and −4.75+1.75×
90, right and left eyes, respectively. He began experiencing
centralmetamorphopsiainthelefteye1monthaftersurgery.
He was referred to our center 3 months later. His vision at
that time was 20/20 in both eyes. The diagnosis of CSCR
was conﬁrmed by fundus exam and OCT subretinal ﬂuid
in the left eye, with a normal exam in the right eye. His
postoperative medications were not recorded. This patient
was followed until spontaneous resolution of his symptoms.
Ten months after PRK his UDVA was 20/15 in the left eye
with no visual complaints.
6. Discussion
CSCRasacomplicationofrefractivesurgeryisrarewithonly
4 previously reported cases [9–12]. These reports identiﬁed 2
hyperopic [9, 10] and 1 myopic patient [11] who developed
CSCR shortly after LASIK and 1 patient [12] who developed
CSCR with CNV. We describe the ﬁrst reported cases of
CSCR to present after PRK.
The annual age-adjusted incidence of CSCR has been
reported to be 5.8 per 100,000, with a male incidence of 9.9
and a female incidence of 1.7 per 100,000 [4]. Although not
directly comparable with population studies, our ﬁndings
support a large male predominance with a low annual in-
cidence of 7.8 per 100,000 eyes after PRK and 3.4 per
100,000 eyes after both PRK and LASIK, based on analysis
of the cases performed at our institution over 6 years. There
were 5 patients who developed CSCR 4 years or more after
LASIK or PRK. These patients were excluded from our
analysisashavingCSCRpotentiallycausedbyLASIKorPRK.
Limitations in our study include the retrospective nature,
possible loss of followup, and development of CSCR after the
time period of medical chart review.
Acute CSCR is a self-resolving disease in approximately
90% of cases [5]. Chronic CSCR often is bilateral, with
symptoms lasting longer than 6 months and can occur with
recurrent disease. CNV has been reported in 0.3–2% of
cases [7]. The high percentage of spontaneously resolving
cases is the reason conservative management is initially
advised. Corticosteroids should be discontinued and if
resolution is not observed within 3 months more aggressive
management can be considered. Half-ﬂuence photodynamic
therapy (PDT) and photocoagulation result in more rapid
resolution of subretinal ﬂuid, and may also limit recurrences
[7].
Previous studies that explored processes leading to vit-
reoretinal pathology following refractive surgery have iden-
tiﬁed two possible exposures. The ﬁrst is potential shock
wave damage in the posterior segment during excimer
laser treatment [1]. This exposure is shared by LASIK and
PRK. However, Krueger et al. reported insigniﬁcant retinal
stress wave amplitudes in experimental models after excimer
photoablation [13]. The second potential risk during LASIK
is the rapid change in intraocular pressure from the suction
ring used to stabilize the microtome [1]. Although less
vacuum is required with femtosecond-laser-assisted LASIK,
the longer ﬂap creation time may still predispose patients
to retinal pathology [2]. Both mechanisms can theoretically
destabilize a structurally altered retina such as in the case of
CSCR.4 Journal of Ophthalmology
Corticosteroids are often used after PRK for their anti-
inﬂammatory properties as an attempt to prevent long-
term sequelae of haze and unpredictable refractive outcomes
[14]. Although, some reports have shown no diﬀerence
in outcomes following PRK treated with or without top-
ical corticosteroids [15, 16], most PRK surgeons reported
using some form of topical corticosteroids postoperatively
[17]. Early corticosteroid treatment has also been reported
more eﬀective than nonsteroidal anti-inﬂammatory drugs
[18].
Multiple routes of corticosteroid administration [19]
havebeenassociatedwithCSCR,includingoral,intravenous,
epidural, intra-articular, inhaled, topical skin application,
and also following intravitreal triamcinolone injections [20].
However, to our knowledge there have been no reported
cases of CSCR following topical ocular corticosteroid use.
The lack of such cases may reﬂect low penetration of topical
drugs in reaching the posterior segment, with even lower
systemic absorption due to further dilution in the tear
ﬁlm [21]. In rabbit eyes, diﬂuprednate showed dramatically
decreased concentrations in the posterior retina and barely
detectable blood concentrations [22], suggesting that even a
highly lipophilic topical corticosteroid with excellent corneal
penetration may not signiﬁcantly alter retinal pathology.
Alternatively, the stress and anxiety of refractive surgery
inducing elevated levels of systemic cortisol may contribute
to exacerbations in CSCR patients.
The dilemma for the surgeon is how to treat such a
patient who develops CSCR after PRK. Continuing topical
corticosteroids may prolong or exacerbate CSCR symptoms,
whereas early removal may decrease control over inﬂamma-
tion potentially leading to long-term haze. Unfortunately,
there is no strong evidence in favor of either management
strategy. Whether topical corticosteroids are discontinued or
changed to less potent formulations, worsening CSCR may
still require consideration of PDT or laser photocoagulation.
Thedecisionwasmadetocontinueourpatientontopical
corticosteroidswithcloseclinicalobservation.Thesubretinal
ﬂuid and symptoms resolved, with no postoperative corneal
haze. The patient was noted to have mild RPE changes
preoperatively which may have indicated prior CSCR disease
activity. A dilated fundoscopic exam is an important part
of both the refractive screening process and postoperative
evaluation when outcomes are not as expected.
In summary, from review of the literature and analysis
of over 4,800 consecutive LASIK and PRK cases at our
institution, we report a low incidence of CSCR after LASIK
or PRK without a direct causal association. CSCR is a multi-
factorial disease with an overall good prognosis. CSCR after
keratorefractive surgery may rarely be induced by extensive
topical corticosteroids, elevated cortisol levels from stress of
thesurgery,ormechanicaldisturbancesafterexcimerlaseror
LASIK ﬂap creation in susceptible patients.
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